Drug-Eluting Balloon in Stable and Unstable Angina

North Karelia Central Hospital220 enrolled

Overview

The purpose of this study is to compare DEB with BMS in CAD patients who are at high risk of bleeding and in whom the use of DES is therefore avoided. Our hypothesis is that PCI with DEB is non-inferior to BMS in the treatment of stable CAD or in ACS (UAP or NSTEMI) in patients at high risk of bleeding.

Stenting has reduced the need of revascularization procedures in stable CAD and ACS as compared to POBA. The use of stents is favored in stable CAD and in ACS according the the present ESC guidelines. However, especially in patients on warfarin or in patients at a high bleeding risk, stenting (and the use of DES in particular) is not recommended because of the longer DAPT required. In these patients, BMS may be used to shorten the duration of DAPT. However, there are problems associated with the treatment using BMS. First of all, a considerable high rate of restenosis is associated with stenting with BMS. Furthermore, stenting may be complicated by the "no-reflow" phenomenon, a coronary dissection or the closure of side branch during the treatment of bifurcation lesions. Implantation of a stent also exposes the patient to stent thrombosis. In contrast, these problems may be avoided by the use of DEB with the provisional BMS strategy. The use of DEB has already been established in the treatment of ISR. Despite the lack of data of RCTs, DEB is already widely used in a variety of clinical situations in which stenting is not desirable. These situations include for example anticoagulation treatment, a high bleeding risk, poor compliance regarding medication, small vessels, bifurcation lesions, long and/or calcified lesions, in case of a marked variation in the vessel reference caliber, in long lesions and in patients with ACS. The all-comer registry data is promising but only hypothesis generating. Thus, it would be very important and ethical to test the efficacy of DEB in a wider patient population in a randomized controlled study. Our hypothesis is that DEB is non-inferior to BMS in the treatment of stable CAD or in ACS (UAP or NSTEMI) in patients on anticoagulation medication or otherwise having a high bleeding risk. Our study sheds light on the use of DEB in PCI of this challenging patient population. In most previous studies, BMS has been routinely added to the DEB treatment. This strategy seems not to yield any benefit but in contrast causes an increased risk of restenosis as compared to the DEB only strategy with provisional stenting. Finally, the current data on the use of DEB in patients with ACS is scarce and our study gives significant information also on this important issue.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

220

Conditions

Coronary Artery Disease

Interventions

drug-eluting balloon (DEB)PROCEDURE

The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is \>20mm or stent malapposition is suspected).

bare-metal stent (BMS)PROCEDURE

The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length \>20mm or stent malapposition is suspected).

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Informed written consent * At least one of the following 1. Patient is using oral anticoagulation (warfarin, dabigatran or rivaroxaban) 2. Anemia (hemoglobin below the threshold: \< 117g/l in women and \< 134 g/l in men) or thrombocytopenia (\<100) detected \<6 months prior the PCI 3. Active malign disease (metastatic cancer or ongoing radio- or chemotherapy) 4. Prior intracerebral hemorrhage or ischemic stroke 5. Severe kidney or liver dysfunction (eGFR \< 30ml/kg/min, liver cirrhosis, BIL \>2x over threshold or ALAT \>3x over threshold) 6. Elective surgery planned \< 12 months after the PCI 7. General frailty for e.g. because of long corticosteroid treatment or generalized cachexia (BMI \< 20 kg/m2) 8. Age ≥ 80 years 9. Inability or suspected inability to use DAPT for 12 months * Either of the following: 10\) Prior bleeding (BARC 2-5) 1. Stable angina or dyspnea and a coronary narrowing causing myocardial ischemia detected in the angiogram. Ischemia is documented by the pressure wire measurement (FFR) or by a non-invasive test such as stress ECG test or perfusion imaging 2. ACS (UAP or NSTEMI): symptoms of heart ischemia ≥ 20 minutes and ≥ 0,5mm ST-depression or transient ST-elevation or T-wave inversion at least in two adjacent leads and/or a high sensitivity troponin (hs-tnt) rise at least one unit above the 99. percentile or at least 50% rise in hs-tnt between two samples taken 3 hours apart * ≥1 de novo lesions in native coronary arteries or bypass vein grafts * Reference diameter of the vessel is 2,5-4,0mm * Lesion or lesions are suitable for PCI Exclusion Criteria: * Inability to give written consent * STEMI * Reference diameter of the vessel is \<2,5mm or \>4,0mm * Bifurcation lesion requiring the stenting of the side branch * Dissection affecting the flow (TIMI\<3) or significant recoil (\>30% in main branch, \>50% in side branch) after predilatation * In-stent restenosis * Life expectancy \< 12 months * Cardiogenic shock at the arrival to the coronary angiography * Uncertainty about neurological recovery e.g. after resuscitation * Unprotected left main (LM) lesion * Chronic total occlusion (CTO)

Locations (4)

Helsinki University Hospital Heart Center

Helsinki, Finland

North Karelia Central Hospital

Joensuu, Finland

Kuopio University Hospital

Kuopio, Finland

Turku University Hospital

Turku, Finland

Outcomes

Primary Outcomes

MACE (Major Adverse Cardiac Event = a composite of cardiac death, nonfatal myocardial infarction (MI) and ischemia driven target lesion revascularization (ID-TLR))

In stable patients, the evidence of ischemia is acquired either by non-invasive testing (for example stress ECG or perfusion imaging) or by pressure wire measurement (FFR) during coronary angiography.

Time frame: At 9 months

ID-TLR (Ischemia Driven Target Lesion Revascularisation)

Time frame: at 36 months

Secondary Outcomes

ID-TLR (Ischemia Driven Target Lesion Revascularisation)

Time frame: At 9 months

Failure to treat the lesion

The failure to deliver the randomized treatment (DEB or BMS) to the target lesion is defined as a failure to treat the lesion.

Time frame: During PCI

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.